Several other equities analysts also recently weighed in on the company. Maxim Group set a $2.00 target price on Interpace Diagnostics Group and gave the company a buy rating in a research report on Monday, October 21st. Oppenheimer assumed coverage on shares of Interpace Diagnostics Group in a research note on Thursday, September 26th. They set an outperform rating and a $3.00 price target on the stock. Finally, HC Wainwright reissued a buy rating and issued a $2.00 price objective on shares of Interpace Diagnostics Group in a research note on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $2.33.
Interpace Diagnostics Group stock opened at $0.45 on Tuesday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.57. Interpace Diagnostics Group has a fifty-two week low of $0.38 and a fifty-two week high of $1.15. The firm has a 50 day moving average price of $0.69 and a 200 day moving average price of $0.75.
Institutional investors have recently made changes to their positions in the company. Perkins Capital Management Inc. increased its stake in shares of Interpace Diagnostics Group by 22.5% during the third quarter. Perkins Capital Management Inc. now owns 2,360,385 shares of the business services provider’s stock worth $1,876,000 after buying an additional 433,135 shares during the period. River & Mercantile Asset Management LLP acquired a new position in Interpace Diagnostics Group during the 2nd quarter worth approximately $468,000. Cambridge Investment Research Advisors Inc. increased its position in shares of Interpace Diagnostics Group by 98.0% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 44,750 shares of the business services provider’s stock valued at $32,000 after purchasing an additional 22,150 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in shares of Interpace Diagnostics Group by 22.3% in the 2nd quarter. Stonepine Capital Management LLC now owns 1,753,184 shares of the business services provider’s stock valued at $1,271,000 after purchasing an additional 319,154 shares in the last quarter. 18.74% of the stock is owned by institutional investors and hedge funds.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Further Reading: Oversold
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.